Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCK | P08631 | 18/20 | 0.57 |
| ▸ | MAPK14 | Q16539 | 18/20 | 0.57 |
| ▸ | MAPK12 | P53778 | 17/20 | 0.57 |
| ▸ | SRC | P12931 | 17/20 | 0.48 |
| ▸ | BRAF | P15056 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3758499 | 0.87 | HCK (0.62) | HCKMAPK14MAPK12SRCBRAF | |
| SCHEMBL9995012 | 0.87 | HCK (0.59) | HCKMAPK14MAPK12SRCBRAF | |
| SCHEMBL12072452 | 0.81 | MAP4K4 (0.43) | HCKMAPK14MAPK12SRCBRAF | |
| SCHEMBL2932677 | 0.79 | BRAF (0.63) | HCKMAPK14MAPK12SRCBRAF | |
| SCHEMBL28933389 | 0.78 | BRAF (0.50) | HCKMAPK14MAPK12BRAF | |
| SCHEMBL4689617 | 0.78 | AAK1 (0.44) | BRAF | |
| SCHEMBL12072463 | 0.78 | SMN1; SMN2 (0.52) | HCKMAPK14MAPK12SRC | |
| SCHEMBL12072470 | 0.76 | GPR119 (0.45) | HCKMAPK14MAPK12SRCBRAF | |
| SCHEMBL2932365 | 0.76 | BRAF (0.64) | HCKMAPK14MAPK12SRCBRAF | |
| SCHEMBL15492470 | 0.75 | MAPK14 (0.48) | MAPK14SRCBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10358445-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2019-07-23 | — | — | US | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| EP-2582700-B1 | RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS | RESPIVERT LTD (GB) | 2016-11-02 | — | — | EP | disclosed |
| US-8933228-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2015-01-13 | — | — | US | disclosed |
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | TSLP, CCL11, RORB | HCK 4116/4885MAPK14 2307/4885MAPK12 2494/4885 |
| US-10358445-B2 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | HCK 4116/4885MAPK14 2307/4885MAPK12 2494/4885 |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | HCK 4116/4885MAPK14 2307/4885MAPK12 2494/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.